Anti-emetic Drugs in Oncogynecology

Czech version

Authors: S. Jirsová ¹; D. Cibula ¹; V. Eretová ¹; P. Freitag ¹; N. Jančárková ¹; P. Hejlová ²; P. Mareš ³; D. Pavlišta ¹; J. Živný ¹
Authors‘ workplace: Gynekologicko-porodnická klinika 1. LF UK a VFN v Praze, přednosta prof. MUDr. J. Živný, DrSc. 2Gynekologicko-porodnické oddělení NsP Mělník, primář MUDr. J. Zmrhal, CSc. 3Onkologická klinika 1. LF UK a VFN v Praze, přednosta doc. MUDr. L. Petruželka, CSc ¹
Published in: Ceska Gynekol 2003; (4): 269-277
Category:

Overview

Objective:
The authors present a survey of available pharmacological possibilities of treatment ofnausea and vomiting aimed at their application in oncological therapy of gynecological neoplasticdiseases.Type of the study: A review article.Name andAddress of the Institution: Gynecological-Obstetrical Clinic,FirstMedicalFaculty, CharlesUniversity and General Faculty Hospital, Praha.Subject and Method of the Study: A survey of published data fromthe Czech and foreign professionalliterature.Conclusion: 5-HT3 receptor antagonists take up the most important position in the antiemetictreatment of oncological patients. They efficiently preventand treatvomiting induced by anticancerdrugs with high and very high emetogenic effect. They have been used as monotherapy or incombination with corticoids. In the treatment of nausea and vomiting or vomiting induced by anticancer drugs with medium or light emetogenic effect, antiemetic preparations from the corticoidseries and dopamine receptor antagonists may be recommended. In the treatment of anticipationvomiting, benzodiazepines are indicated for their anxiolytic and psychosedative influence.

Key words:
antiemetics, estrones, 5-HT3 antagonists

Full text is not available online.

If interested in a scan of this journal, contact NTO ČLS JEP.